ArticleResearch square2025
Syringe Service Program Utilization, Behavioral, and Experiential Factors Associated with Greater Naloxone Protection in a Longitudinal Cohort of People Who Use Illicit Opioids in New York City.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
10 authors.
Funding
Abstract
Background: Despite efforts to blanket high-mortality communities with no-cost naloxone, drug checking technologies, and alternatives to using opioids alone, there remains a considerable lack of knowledge about how exposure to these low-threshold interventions may impact rates of naloxone protection. Methods: People who used illicit opioids in New York City were surveyed between April 2019-April 2022. Results: Among 428 study participants (mean age 49 years, 64% cisgender male, 35% Black, 41% Latinx), several factors were significantly associated with naloxone protection levels. Visiting a syringe service program (SSP) in the last three months was significantly associated with higher naloxone protection in the full sample (IRR = 1.94, 95% CI: 1.38-2.74) and among males (IRR = 1.84, 95% CI: 1.29-2.64). Significantly lower naloxone protection was also observed among Latinx participants compared to White individuals in the full sample (IRR = 0.64, 95% CI: 0.44-0.94) and among females aged 57-72 years compared to those aged 20-40 years (IRR = 0.39, 95% CI: 0.16-0.95). Participants living with someone who does not use opioids (vs. living with someone who uses opioids) showed significantly lower naloxone protection levels in the full sample (IRR = 0.54, 95% CI: 0.37-0.80) and among males (IRR = 0.46, 95% CI: 0.29-0.73). Other factors associated with lower naloxone protection in the full sample included any opioid withdrawal in the last 30 days, higher pain severity, and more negative life events. Conversely, receiving social support from another person who uses opioids was significantly associated with higher naloxone protection in the full sample (IRR = 1.14, 95% CI: 1.07-1.22) and among females (IRR = 1.30 95% CI 1.16-1.46). Additional factors associated with greater naloxone protection in the full sample included: concurrent opioid and stimulant use, heroin/injection use (1-15 days), fentanyl test strip use, lifetime opioid overdose, and number of lifetime arrests. Conclusion: Findings suggest positive impacts of syringe service program engagement and use of harm reduction best-practices and interventions on promoting naloxone protection and highlight differential associations. These results can be used to inform culturally-sensitive and tailored outreach to people at risk of overdose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.